277
Views
2
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

The in vitro Activity of Echinocandins Against Clinical Trichophyton rubrum Isolates and Review of the Susceptibility of T. rubrum to Echinocandins Worldwide

ORCID Icon, , , , , , & show all
Pages 5395-5403 | Received 29 Jun 2023, Accepted 12 Aug 2023, Published online: 18 Aug 2023

References

  • Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses. 2008;51(Suppl 4):2–15. doi:10.1111/j.1439-0507.2008.01606.x
  • White TC, Findley K, Dawson TL Jr, et al. Fungi on the skin: dermatophytes and Malassezia. Cold Spring Harb Perspect Med. 2014;4(8):a019802. doi:10.1101/cshperspect.a019802
  • Singh A, Masih A, Khurana A, et al. High terbinafine resistance in Trichophyton interdigitale isolates in Delhi, India harbouring mutations in the squalene epoxidase gene. Mycoses. 2018;61(7):477–484. doi:10.1111/myc.12772
  • Tang C, Kong X, Ahmed SA, et al. Taxonomy of the Trichophyton mentagrophytes/T. interdigitale species complex harboring the highly virulent, multiresistant genotype T. indotineae. Mycopathologia. 2021;186(3):315–326. doi:10.1007/s11046-021-00544-2
  • Gupta AK, Foley KA, Versteeg SG. New antifungal agents and new formulations against dermatophytes. Mycopathologia. 2017;182(1–2):127–141. doi:10.1007/s11046-016-0045-0
  • Mukherjee PK, Leidich SD, Isham N, Leitner I, Ryder NS, Ghannoum MA. Clinical Trichophyton rubrum strain exhibiting primary resistance to terbinafine. Antimicrob Agents Chemother. 2003;47(1):82–86. doi:10.1128/aac.47.1.82-86.2003
  • Schøsler L, Andersen LK, Arendrup MC, Sommerlund M. Recurrent terbinafine resistant Trichophyton rubrum infection in a child with congenital ichthyosis. Pediatr Dermatol. 2018;35(2):259–260. doi:10.1111/pde.13411
  • Suzuki S, Mano Y, Furuya N, Fujitani K. Discovery of terbinafine low susceptibility Trichophyton rubrum strain in Japan. Biocontrol Sci. 2018;23(3):151–154. doi:10.4265/bio.23.151
  • Salehi Z, Shams-Ghahfarokhi M, Razzaghi-Abyaneh M. Antifungal drug susceptibility profile of clinically important dermatophytes and determination of point mutations in terbinafine-resistant isolates. Eur J Clin Microbiol Infect Dis. 2018;37(10):1841–1846. doi:10.1007/s10096-018-3317-4
  • Osborne CS, Hofbauer B, Favre B, Ryder NS. In vitro analysis of the ability of Trichophyton rubrum to become resistant to terbinafine. Antimicrob Agents Chemother. 2003;47(11):3634–3636. doi:10.1128/aac.47.11.3634-3636.2003
  • Hryncewicz-Gwóźdź A, Kalinowska K, Plomer-Niezgoda E, Bielecki J, Jagielski T. Increase in resistance to fluconazole and itraconazole in Trichophyton rubrum clinical isolates by sequential passages in vitro under drug pressure. Mycopathologia. 2013;176(1–2):49–55. doi:10.1007/s11046-013-9655-y
  • Ghelardi E, Celandroni F, Gueye SA, et al. Potential of Ergosterol synthesis inhibitors to cause resistance or cross-resistance in Trichophyton rubrum. Antimicrob Agents Chemother. 2014;58(5):2825–2829. doi:10.1128/aac.02382-13
  • Ebert A, Monod M, Salamin K, et al. Alarming India-wide phenomenon of antifungal resistance in dermatophytes: a multicentre study. Mycoses. 2020;63(7):717–728. doi:10.1111/myc.13091
  • Jiang Y, Luo W, Verweij PE, et al. Regional differences in antifungal susceptibility of the prevalent dermatophyte Trichophyton rubrum. Mycopathologia. 2021;186(1):53–70. doi:10.1007/s11046-020-00515-z
  • Uhrlaß S, Verma SB, Gräser Y, et al. Trichophyton indotineae-an emerging pathogen causing recalcitrant dermatophytoses in India and worldwide-a multidimensional perspective. J Fungi. 2022;8(7). doi:10.3390/jof8070757
  • Cappelletty D, Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy. 2007;27(3):369–388. doi:10.1592/phco.27.3.369
  • Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;62(4):e1–e50. doi:10.1093/cid/civ933
  • Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of Aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;63(4):e1–e60. doi:10.1093/cid/ciw326
  • Bao YQ, Wan Z, Li RY. In vitro antifungal activity of micafungin and caspofungin against dermatophytes isolated from China. Mycopathologia. 2013;175(1–2):141–145. doi:10.1007/s11046-012-9571-6
  • Aktas AE, Yigit N, Aktas A, Gozubuyuk SG. Investigation of in vitro activity of five antifungal drugs against dermatophytes species isolated from clinical samples using the E-Test Method. Eurasian J Med. 2014;46(1):26–31. doi:10.5152/eajm.2014.05
  • Badali H, Mohammadi R, Mashedi O, de Hoog GS, Meis JF, de Hoog GS. In vitro susceptibility patterns of clinically important Trichophyton and Epidermophyton species against nine antifungal drugs. Mycoses. 2015;58(5):303–307. doi:10.1111/myc.12315
  • Risslegger B, Lass-Flörl C, Blum G, Lackner M. Evaluation of a modified EUCAST fragmented-mycelium inoculum method for in vitro susceptibility testing of dermatophytes and the activity of novel antifungal agents. Antimicrob Agents Chemother. 2015;59(6):3675–3682. doi:10.1128/aac.04381-14
  • Baghi N, Shokohi T, Badali H, et al. In vitro activity of new azoles luliconazole and lanoconazole compared with ten other antifungal drugs against clinical dermatophyte isolates. Med Mycol. 2016;54(7):757–763. doi:10.1093/mmy/myw016
  • Moriarty B, Hay R, Morris-Jones R. The diagnosis and management of tinea. BMJ. 2012;345(jul10 1):e4380. doi:10.1136/bmj.e4380
  • Su H, Packeu A, Ahmed SA, et al. Species distinction in the Trichophyton rubrum complex. J Clin Microbiol. 2019;57(9). doi:10.1128/JCM.00352-19
  • Szymański M, Chmielewska S, Czyżewska U, Malinowska M, Tylicki A. Echinocandins - structure, mechanism of action and use in antifungal therapy. J Enzyme Inhib Med Chem. 2022;37(1):876–894. doi:10.1080/14756366.2022.2050224
  • Chen SC, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs. 2011;71(1):11–41. doi:10.2165/11585270-000000000-00000
  • Arendrup MC, Kahlmeter G, Guinea J, Meletiadis J. How to: perform antifungal susceptibility testing of microconidia-forming dermatophytes following the new reference EUCAST method E.Def 11.0, exemplified by Trichophyton. Clin Microbiol Infect. 2021;27(1):55–60. doi:10.1016/j.cmi.2020.08.042
  • Cantón E, Pemán J, Hervás D, Espinel-Ingroff A. Examination of the in vitro fungicidal activity of echinocandins against Candida lusitaniae by time-killing methods. J Antimicrob Chemother. 2013;68(4):864–868. doi:10.1093/jac/dks489
  • Deng S, Ansari S, Ilkit M, et al. In vitro antifungal susceptibility profiles of 12 antifungal drugs against 55 Trichophyton schoenleinii isolates from Tinea Capitis Favosa Patients in Iran, Turkey, and China. Antimicrob Agents Chemother. 2017;61(2). doi:10.1128/AAC.01753-16
  • Su H, Zhu M, Tsui CK, et al. Potency of olorofim (F901318) compared to contemporary antifungal agents against clinical Aspergillus fumigatus isolates, and review of azole resistance phenotype and genotype epidemiology in China. Antimicrob Agents Chemother. 2021;65(5). doi:10.1128/AAC.02546-20